Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Prepaid Assets: 2015-2025

Historic Prepaid Assets for Spyre Therapeutics (SYRE) over the last 10 years, with Sep 2025 value amounting to $18.4 million.

  • Spyre Therapeutics' Prepaid Assets rose 168.62% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year increase of 168.62%. This contributed to the annual value of $5.4 million for FY2024, which is 139.27% up from last year.
  • Latest data reveals that Spyre Therapeutics reported Prepaid Assets of $18.4 million as of Q3 2025, which was up 50.23% from $12.3 million recorded in Q2 2025.
  • Spyre Therapeutics' 5-year Prepaid Assets high stood at $18.4 million for Q3 2025, and its period low was $2.2 million during Q3 2023.
  • For the 3-year period, Spyre Therapeutics' Prepaid Assets averaged around $6.6 million, with its median value being $5.4 million (2024).
  • As far as peak fluctuations go, Spyre Therapeutics' Prepaid Assets crashed by 72.23% in 2023, and later skyrocketed by 237.99% in 2024.
  • Spyre Therapeutics' Prepaid Assets (Quarterly) stood at $4.9 million in 2021, then climbed by 24.74% to $6.2 million in 2022, then slumped by 63.53% to $2.3 million in 2023, then soared by 139.27% to $5.4 million in 2024, then spiked by 168.62% to $18.4 million in 2025.
  • Its Prepaid Assets was $18.4 million in Q3 2025, compared to $12.3 million in Q2 2025 and $4.9 million in Q1 2025.